about
Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy.Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up.Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.Predictive factors for lymph node metastasis in additional gastrectomy after endoscopic resection of cT1aN0 gastric cancer.Effect of Preoperative Nutritional Status on Surgical Site Infection in Colorectal Cancer Resection.Long-term prognostic outcome of cT1 gastric cancer patients who underwent laparoscopic gastrectomy after 5-year follow-up.Potential benefits of laparoscopy-assisted proximal gastrectomy with esophagogastrostomy for cT1 upper-third gastric cancer.The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios.Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer.Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer.Laparoscopically Assisted Proximal Gastrectomy with Esophagogastrostomy Using a Novel "Open-Door" Technique : LAPG with Novel Reconstruction.Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared With laparoscopy-assisted distal gastrectomy: A cross-sectional postal questionnaire survey.DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer.Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy.Prognostic impact of venous invasion in stage IB node-negative gastric cancer.Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy.A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trialLaparoscopic antireflux surgery improves esophageal body motility in patients with severe reflux esophagitisVideo-assisted thoracic surgery and jejunal reconstruction in a case of situs inversus totalis with esophageal cancerA phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junctionComparison of double-flap and OrVil techniques of laparoscopy-assisted proximal gastrectomy in preventing gastroesophageal reflux: a retrospective cohort studySafety and Feasibility of Robotic Distal Gastrectomy for Stage IA Gastric Cancer: A Phase II TrialDelta-shaped anastomosis vs circular stapler anastomosis after laparoscopic distal gastrectomy with Billroth I reconstruction: A randomized controlled trialEpigenetic biomarkers of promoter DNA methylation in the new era of cancer treatmentRe-emerging role of macroscopic appearance in treatment strategy for gastric cancerCD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric CancerPrevention of intra-thoracic recurrent laryngeal nerve injury with robot-assisted esophagectomy
P50
Q33560108-B2EE0840-27CC-4479-85F1-EFEE491412E2Q33599536-C4889A12-DE8B-4268-B7FE-0E2B1A799858Q38558734-63F026E7-7F51-4E39-AE44-F2082D041C13Q38932852-69291C49-0C69-42AB-A592-E58247A8341DQ40598088-75F9336C-DD65-425C-8926-FCC21C64C091Q40843817-A0931598-0DF4-479A-BB91-67CD11B86F37Q41174446-A5010F44-9819-468F-B8DC-54FA2CDE5CF6Q46207048-3F97EA0B-594C-4BBA-BE95-202719EF28DCQ47190014-5B186B2E-5F11-4682-8CFF-AFA1C67F91D7Q47428360-378577A2-3744-459B-8EB0-ED6F4F09112BQ47598167-6D878E9C-A1B2-43E0-9E34-F6DECE897D60Q47642386-FC2E716C-4AC1-4CA8-A431-CBECF597F178Q48187540-19A43BDB-38C9-4D83-99E8-8A17D302AEF2Q49335043-18708191-BC82-48DA-AAD1-E723F92FCBFFQ50703559-C5CDE8A7-B500-4010-B5EB-03F3CB38A3FCQ50911593-482C4274-7D38-4185-A2BA-8DC8B7696DBBQ57036548-C7F4059D-1931-49FE-8ADD-91B0EEC6A724Q87308287-87B6AF51-78E1-4983-A5D0-0443F413639BQ88460586-6CC1B793-1132-4C0E-A275-3F9922177A11Q89986435-1F4285FD-BEE7-40D5-B0D7-90BA5CD54199Q90905318-A6C230C3-1943-4A97-8A9A-261FCEB3797AQ91651237-F656634D-5B20-4717-99B0-2D8F294B8DD7Q91785976-57216794-9FD2-409A-B471-0A15A6E29545Q91839454-8D4C7449-833D-4523-B185-D7934A3DBA3AQ92690575-BD0B906F-A2EB-4060-9E0B-08D122D5C638Q93029464-6EF153BF-18FE-414E-B742-8C2F5452B829Q96138382-C5FC8B80-FD3B-49FC-B8F9-6C087A5E7248
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kei Hosoda
@ast
Kei Hosoda
@en
Kei Hosoda
@es
Kei Hosoda
@nl
Kei Hosoda
@sl
type
label
Kei Hosoda
@ast
Kei Hosoda
@en
Kei Hosoda
@es
Kei Hosoda
@nl
Kei Hosoda
@sl
prefLabel
Kei Hosoda
@ast
Kei Hosoda
@en
Kei Hosoda
@es
Kei Hosoda
@nl
Kei Hosoda
@sl
P106
P21
P31
P496
0000-0002-9787-2889
P569
2000-01-01T00:00:00Z